Literature DB >> 32873061

Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.

Adkhamjon Mamatkulov1, Evgeniya Kazakova1, Nargiz Ibadullaeva1, Elizaveta Joldasova1, Allabergan Bayjanov1, Erkin Musabaev1, Nataliya Kan1, Dildora Mustafaeva2, Aleksey Lebedev3, Marina Bobkova3, Elena Kazennova3, Lev Zohrabyan4.   

Abstract

To evaluate the national prevalence of antiretroviral therapy (ART)-resistant HIV-1 viruses among both ART-initiators (pretreatment drug resistance, PDR) and ART-failure HIV patients in Uzbekistan. A nation-wide, cross-sectional active HIV-1 PDR surveillance was conducted in Uzbekistan from 2015 to 2016. In total, 713 blood plasma samples from adults were collected, including samples from ART-naive patients initiating ART and ART-failure HIV patients. HIV-1 genome polregion viral sequences were obtained from 309 patients, of those 106 on ART and 203 on ART-initiators. Analysis of HIV-1 subtypes and drug resistance mutations (DRMs) to HIV protease and reverse transcriptase inhibitors was performed. Among all the viruses studied, HIV-1 CRF 02_AG recombinant was the most common-57% (176/309). The second major group was represented by A1-40.5% (125/309). Two viruses were found to be recombinants formed by subtypes A1 and CRF02_AG sequences. ART-naive cohort I (PDR) included six samples that contained at least one surveillance drug resistance mutation (SDRM) (2.96%), with the most common being K103N mutation (4/6). In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106). The significant difference in frequency of mutations was found between two dominant subtypes, A1 and CRF02_AG. The molecular epidemiological profile of HIV infection in Uzbekistan has changed toward a predominance of CRF02_AG viruses. In the first national-scale study of the PDR prevalence, it was found to be relatively low (2.96%). The DR mutations in failure patients correspond to the main therapy regimens (NRTI/NNRTI) adopted in the country. The observations provide new evidence for differences in ART efficacy and resistance profiles for different subtypes.

Entities:  

Keywords:  HIV; Uzbekistan; mutations; resistance; subtype

Year:  2020        PMID: 32873061     DOI: 10.1089/AID.2020.0096

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Identifying HIV-1 Transmission Clusters in Uzbekistan through Analysis of Molecular Surveillance Data.

Authors:  Aleksey Lebedev; Anna Kuznetsova; Kristina Kim; Ekaterina Ozhmegova; Anastasiia Antonova; Elena Kazennova; Aleksandr Tumanov; Adkhamjon Mamatkulov; Evgeniya Kazakova; Nargiz Ibadullaeva; Krestina Brigida; Erkin Musabaev; Dildora Mustafaeva; Visola Rakhimova; Marina Bobkova
Journal:  Viruses       Date:  2022-07-29       Impact factor: 5.818

2.  Detection of Patient HIV-1 Drug Resistance Mutations in Russia's Northwestern Federal District in Patients with Treatment Failure.

Authors:  Alexander N Shchemelev; Yulia V Ostankova; Elena B Zueva; Alexander V Semenov; Areg A Totolian
Journal:  Diagnostics (Basel)       Date:  2022-07-28

3.  Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries.

Authors:  Alina Kirichenko; Dmitry Kireev; Alexey Lopatukhin; Anastasia Murzakova; Ilya Lapovok; Daria Saleeva; Natalya Ladnaya; Agigat Gadirova; Sabina Ibrahimova; Aygun Safarova; Trdat Grigoryan; Arshak Petrosyan; Tatevik Sarhatyan; Elena Gasich; Anastasia Bunas; Iryna Glinskaya; Pavel Yurovsky; Rustam Nurov; Alijon Soliev; Laylo Ismatova; Erkin Musabaev; Evgeniya Kazakova; Visola Rakhimova; Vadim Pokrovsky
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.